Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026GlobeNewsWire · 2 days ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLGlobeNewsWire · Oct 5, 2026
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewsWire · Oct 5, 2026
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5thGlobeNewsWire · Oct 2, 2026
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced MelanomaGlobeNewsWire · Oct 1, 2026
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewsWire · Oct 1, 2026Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.69 | -$0.72 | Miss |
| Jun 29, 2026 | -$0.73 | -$0.76 | Miss |
| Feb 3, 2026 | -$0.77 | -$0.77 | Miss |
| Nov 6, 2025 | -$0.87 | -$0.90 | Miss |
| Aug 7, 2025 | -$0.83 | -$0.95 | Miss |
| May 22, 2025 | -$0.75 | -$0.82 | Miss |